Benzinga··PrnewswireIceCure's Kidney Cancer Data Shows Strong Promise Ahead of European Presentation
IceCure Medical reports positive 5-year results from ICESECRET trial, demonstrating 83.9% recurrence-free rates in kidney cancer patients using cryoablation technology.
ICCMclinical trialkidney cancer